Anti-Human CD3 x GPRC5D (Talquetamab) (C3280-1.0mg)

Anti-Human CD3 x GPRC5D bispecific antibodies offer a promising therapeutic approach for multiple myeloma (MM) by targeting both T-cells and myeloma cells. GPRC5D (G protein- coupled receptor class C group 5 member D) is expressed in about 90% of malignant plasma cells in MM patients, making it an appealing target for treatment. Studies have shown that these bispecific antibodies effectively kill MM cells in both in vitro and in vivo settings, including in patients with relapsed or refractory disease. Their efficacy is linked to the levels of GPRC5D expression, and they have demonstrated significant tumor growth inhibition through the recruitment of T-cells. However, resistance mechanisms, such as genetic inactivation or epigenetic silencing of GPRC5D, have been observed in some patients. Despite these challenges, anti-CD3 x GPRC5D bispecific antibodies hold great potential as a potent treatment for a broad range of MM patients, either as a standalone therapy or in combination with other agents1-3. JNJ-64407564, also known as Talquetamab, is a first-in-class bispecific antibody targeting GPRC5D and CD3 for treating relapsed or refractory multiple myeloma (RRMM). In clinical trials, Talquetamab has demonstrated significant efficacy, with overall response rates exceeding 71% in patients exposed to at least three different classes of therapy. By redirecting T cells to attack GPRC5D-expressing myeloma cells, Talquetamab induces strong cytotoxic effects. The FDA granted Talquetamab accelerated approval in August 2023 for treating adults with RRMM who have undergone at least four prior lines of therapy, marking it as a promising new option for patients with limited treatment alternatives2,4,5.